HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy
Robert K. Heaton, David B. Clifford, Donald R Franklin, Steven Paul Woods, Christopher F. Ake, Florin Vaida, Ronald J. Ellis, Scott Lee Letendre, Thomas D. Marcotte, Joseph Hampton Atkinson, Mónica Rivera Mindt, Ofilio Vigil, Michael J. Taylor, Ann C. Collier, Christina M. Marra, Benjamin B. Gelman, Justin Charles McArthur, Susan Morgello, David Martin Simpson, John Allen McCutchan, IAN S. ABRAMSON, Anthony C. Gamst, Christine Fennema‐Notestine, Terry L. Jernigan, JillianW Wong, Igor Grant
Neurology · 2010 · 2,385 citationsOpen access
Abstract
OBJECTIVES: This is a cross-sectional, observational study to determine the frequency and associated features of HIV-associated neurocognitive disorders (HAND) in a large, diverse sample of infected individuals in the era of combination antiretroviral therapy (CART). METHODS: A total of 1,555 HIV-infected adults were recruited from 6 university clinics across the United States, with minimal exclusions. We used standardized neuromedical, psychiatric, and neuropsychological (NP) examinations, and recently published criteria for diagnosing HAND and classifying 3 levels of comorbidity (minimal to severe non-HIV risks for NP impairment). RESULTS: Fifty-two percent of the total sample had NP impairment, with higher rates in groups with greater comorbidity burden (40%, 59%, and 83%). Prevalence estimates for specific HAND diagnoses (excluding severely confounded cases) were 33% for asymptomatic neurocognitive impairment, 12% for mild neurocognitive disorder, and only 2% for HIV-associated dementia (HAD). Among participants with minimal comorbidities (n = 843), history of low nadir CD4 was a strong predictor of impairment, and the lowest impairment rate on CART occurred in the subset with suppressed plasma viral loads and nadir CD4 ≥200 cells/mm(3) (30% vs 47% in remaining subgroups). CONCLUSIONS: The most severe HAND diagnosis (HAD) was rare, but milder forms of impairment remained common, even among those receiving CART who had minimal comorbidities. Future studies should clarify whether early disease events (e.g., profound CD4 decline) may trigger chronic CNS changes, and whether early CART prevents or reverses these changes.
Cite this paper
Heaton, R. K., Clifford, D. B., Franklin, D. R., Woods, S. P., Ake, C. F., Vaida, F., Ellis, R. J., Letendre, S. L., Marcotte, T. D., Atkinson, J. H., Mindt, M. R., Vigil, O., Taylor, M. J., Collier, A. C., Marra, C. M., Gelman, B. B., McArthur, J. C., Morgello, S., Simpson, D. M., … Group, F. the C. (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology, 75(23), 2087–2096. https://doi.org/10.1212/wnl.0b013e318200d727
Read it with every claim anchored
Add this paper to a project, ask questions of it, and get answers that point to the exact passage.
Start freeRelated papers
- Structure, function and diversity of the healthy human microbiome2012
- The amyloid hypothesis of Alzheimer's disease at 25 years2016
- Lecanemab in Early Alzheimer’s Disease2022
- The Microbiota-Gut-Brain Axis2019
- Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity2013
Metadata from OpenAlex (CC0). Citations are generated from the published record.